ABOUT RENAISSANCE

Novel therapies to enhance the lives of children around the world

We are a global, clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world.

Our lead candidate, a humanised anti-GD2 antibody called Hu14.18K322A (Hu14.18) has completed Phase II trials, where it showed significant improvement in clinical outcomes for children with newly diagnosed high-risk neuroblastoma. A combination of treatment with Hu14.18 and chemotherapy led to an overall survival rate of 86%, with potential for reduced immunogenicity and tolerability compared to the current standard of care.

Overview

Our Team

Our experienced executive management team and scientific advisory board have taken multiple candidates from the pre-clinical stage through to clinical trials and commercialisation.

Management

  • Mr. Lee Morley

    CHAIRMAN

    Before co-founding Renaissance, Lee was founder and CEO EUSA Pharma (sold to Recordati in 2021 for €750m). Previous roles included Head of Commercial at Jazz Pharma (formerly EUSA Pharma) and Director of Sales at Cephalon (formerly Zeneus Pharma). Lee started his career at MSD.

  • Mr. Simon Ball

    CEO

    Prior to co-founding Renaissance, Simon was the Global Head of Business Development and UK/Nordics General Manager at Sigma Tau Rare Disease. Simon’s previous roles include: Head of BD Asia Pacific/North Asia/Developing Markets at GSK, Director BD at Takeda, VP BD at EUSA, and Director of BD at Cephalon (formerly Zeneus Pharma). Simon started his career at MSD.

  • Dr. Jonathan Morgan, MBBS

    CMO

    Jon qualified at Guys & St Thomas’s hospital, completed general medical trading at various hospitals in the UK and practised as a Specialist Registrar in the West Midlands deanery prior to moving into industry. Before his appointment with Renaissance, Jon was the Head of Medical at Eusa Pharma (sold to Recordati 2021 for €750m). Other roles have included the Head of Medical Affairs at both Jazz Pharma (formerly EUSA Pharma) and GSK. Jon has led the medical, safety, regulatory and clinical development functions across a range of oncology and rare disease small molecules and biologics, taking products from late stage development to regulatory approval, launch and commercialisation in a range of global territories.

  • Dr. Debra Nevin, PhD

    CTO

    Debra has over 30 years experience in Biologics with a specialty interest in the area of monoclonal antibody production and supply chain development. Debra held senior roles in biologics manufacturing at Celltech, Oxford GlycoSciences, UCB and Lonza Biologics and for the last 12 years as the CEO & Principle Consultant at Amethyst Pharma Ltd. She has led many CMC programs around the world, supporting Biotech companies and CMOs for GMP manufacturing, including several License approvals and many INDs.

Scientific Advisory Board

  • Dr. Dee Athwal, PhD

    Dee has over 3 decades of experience in antibody engineering and development, covering multiple antibody programs now on the market. Dee has managed and led programs spanning oncology, autoimmune, inflammatory and CNS from discovery through clinical development.